ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This study is a multicentric randomized trial evaluating the efficacy of the combination
ACVBP+rituximab compared to the combination of CHOP+rituximab in patients aged from 18 to 59
years with diffuse large B-cell lymphoma and one factor of the age-adjusted international
prognostic index (IPI).